Molecular tumor board for gynecologic malignancies: the real-world experience from the Department for Gynecology and Gynecologic Oncology of Kliniken Essen-Mitte.

Objective: Advances in cancer research are leading to a shift from the traditional "organ-centric" therapies to a personalized tumor biology-based approach. Here, we report outcomes in patients who underwent molecular tumor profiling for gynecologic malignancies.

Methods: We prospectively recorded clinical and pathologic characteristics, follow-up data, next-generation sequencing results, and tumor board recommendations of all patients who underwent molecular tumor board at the Department for Gynecologic Oncology, Kliniken Essen-Mitte, from March 2019 to March 2024.